MAM
TCRX icon

Marquette Asset Management’s TScan Therapeutics TCRX Stock Holding History

Marquette Asset Management’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-28,895
Closed -$88K – 276
2022
Q3 		$88K Hold
28,895
– – 0.03% 116
2022
Q2 		$91K Hold
28,895
– – 0.03% 136
2022
Q1 		$81K Buy
28,895
+7,277
+34% +$31.5K 0.02% 163
2021
Q4 		$97K Buy
+21,618
New +$156K 0.02% 153

Other funds holding TCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Marquette Asset Management's TCRX Position: Q4 2022 in Review

Marquette Asset Management sold out of TScan Therapeutics (TCRX) in Q4 2022, closing a stake of 28,895 shares — an estimated $88K sold.

Marquette Asset Management first reported a position in TCRX in Q4 2021 and held it in 4 quarters. The position peaked at $97K in Q4 2021. 28 funds tracked by Wall St. Rank hold TCRX as of Q4 2022.

  • Marquette Asset Management reported no remaining TScan Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Marquette Asset Management sold 28,895 TScan Therapeutics shares in Q4 2022, an estimated $88K.
  • Marquette Asset Management first reported a position in TScan Therapeutics in Q4 2021 and held it in 4 quarters.
  • Marquette Asset Management's TScan Therapeutics position peaked at $97K in Q4 2021.
  • 28 funds tracked by Wall St. Rank held TScan Therapeutics as of Q4 2022.

Based on Marquette Asset Management's 13F filing for Q4 2022, filed 12 Jan 2023.